-
1
-
-
33846572874
-
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
-
1:STN:280:DC%2BD2s%2FlsFOmug%3D%3D 17082464
-
Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007;68(5):384-6.
-
(2007)
Neurology.
, vol.68
, Issue.5
, pp. 384-386
-
-
Dorsey, E.R.1
Constantinescu, R.2
Thompson, J.P.3
Biglan, K.M.4
Holloway, R.G.5
Kieburtz, K.6
-
2
-
-
0017082987
-
Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis
-
1:CAS:528:DyaE28XlsVSqtb4%3D 956814
-
Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm. 1976;38(3-4):277-301.
-
(1976)
J Neural Transm
, vol.38
, Issue.3-4
, pp. 277-301
-
-
Riederer, P.1
Wuketich, S.2
-
3
-
-
84938948969
-
New clinical subtypes of Parkinson disaese and their longitudinal progression: A prospective cohort comparison with other phenotypes
-
26076039
-
Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New clinical subtypes of Parkinson disaese and their longitudinal progression: a prospective cohort comparison with other phenotypes. JAMA Neurol. 2015;72(8):863-73.
-
(2015)
JAMA Neurol.
, vol.72
, Issue.8
, pp. 863-873
-
-
Fereshtehnejad, S.M.1
Romenets, S.R.2
Anang, J.B.3
Latreille, V.4
Gagnon, J.F.5
Postuma, R.B.6
-
4
-
-
0031668934
-
The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality
-
1:CAS:528:DyaK1cXmtFGktb8%3D 9749592
-
Marsden CD, Olanow CW. The causes of Parkinson's disease are being unraveled and rational neuroprotective therapy is close to reality. Ann Neurol. 1998;44(3 Suppl 1):S189-96.
-
(1998)
Ann Neurol
, vol.44
, Issue.3
, pp. S189-S196
-
-
Marsden, C.D.1
Olanow, C.W.2
-
5
-
-
0141741347
-
Parkinson's disease: Mechanisms and models
-
1:CAS:528:DC%2BD3sXnsFait7o%3D 12971891
-
Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39(6):889-909.
-
(2003)
Neuron
, vol.39
, Issue.6
, pp. 889-909
-
-
Dauer, W.1
Przedborski, S.2
-
6
-
-
84873443346
-
Parkinson's disease: Evidence for environmental risk factors
-
1:CAS:528:DC%2BC3sXjsVWhtrw%3D
-
Kieburtz K, Wunderle KB. Parkinson's disease: evidence for environmental risk factors. Mov Disord Off J Mov Disord Soc. 2013;28(1):8-13.
-
(2013)
Mov Disord off J Mov Disord Soc
, vol.28
, Issue.1
, pp. 8-13
-
-
Kieburtz, K.1
Wunderle, K.B.2
-
7
-
-
84873478145
-
Trial designs used to study neuroprotective therapy in Parkinson's disease
-
1:CAS:528:DC%2BC3sXjsVWht74%3D
-
Lang AE, Melamed E, Poewe W, Rascol O. Trial designs used to study neuroprotective therapy in Parkinson's disease. Mov Disord Off J Mov Disord Soc. 2013;28(1):86-95.
-
(2013)
Mov Disord off J Mov Disord Soc
, vol.28
, Issue.1
, pp. 86-95
-
-
Lang, A.E.1
Melamed, E.2
Poewe, W.3
Rascol, O.4
-
8
-
-
0037461309
-
Neuroprotective agents for clinical trials in Parkinson's disease: A systematic assessment
-
1:STN:280:DC%2BD3s7ovVKitg%3D%3D 12707423
-
Ravina BM, Fagan SC, Hart RG, Hovinga CA, Murphy DD, Dawson TM, et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology. 2003;60(8):1234-40.
-
(2003)
Neurology.
, vol.60
, Issue.8
, pp. 1234-1240
-
-
Ravina, B.M.1
Fagan, S.C.2
Hart, R.G.3
Hovinga, C.A.4
Murphy, D.D.5
Dawson, T.M.6
-
9
-
-
0036719861
-
Neuroprotection by propargylamines in Parkinson's disease: Suppression of apoptosis and induction of prosurvival genes
-
1:CAS:528:DC%2BD38XmsVCit7c%3D 12200198
-
Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol. 2002;24(5):675-82.
-
(2002)
Neurotoxicol Teratol
, vol.24
, Issue.5
, pp. 675-682
-
-
Maruyama, W.1
Akao, Y.2
Carrillo, M.C.3
Kitani, K.4
Youdium, M.B.5
Naoi, M.6
-
10
-
-
0024457355
-
A multicenter controlled clinical trial in early Parkinson's disease
-
Parkinson Study Group. Arch Neurol.
-
DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol. 1989;46(10):1052'60.
-
(1989)
DATATOP
, vol.46
, Issue.10
, pp. 1052-1060
-
-
-
11
-
-
0024456653
-
Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. New Engl
-
Parkinson Study Group
-
Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. The Parkinson Study Group. New Engl. J Med. 1989;321(20):1364-71.
-
(1989)
J Med.
, vol.321
, Issue.20
, pp. 1364-1371
-
-
-
12
-
-
0027530638
-
Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease
-
Parkinson Study Group
-
Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. New Engl J Med. 1993;328(3):176-83.
-
(1993)
New Engl J Med.
, vol.328
, Issue.3
, pp. 176-183
-
-
-
13
-
-
0028858370
-
The effect of deprenyl and levodopa on the progression of Parkinson's disease
-
1:CAS:528:DyaK28XlsVWhug%3D%3D 7486869
-
Olanow CW, Hauser RA, Gauger L, Malapira T, Koller W, Hubble J, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol. 1995;38(5):771-7.
-
(1995)
Ann Neurol.
, vol.38
, Issue.5
, pp. 771-777
-
-
Olanow, C.W.1
Hauser, R.A.2
Gauger, L.3
Malapira, T.4
Koller, W.5
Hubble, J.6
-
15
-
-
0036894795
-
A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study
-
Parkinson Study Group
-
Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59(12):1937-43.
-
(2002)
Arch Neurol.
, vol.59
, Issue.12
, pp. 1937-1943
-
-
-
16
-
-
13444302612
-
A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: The PRESTO study
-
Parkinson Study Group
-
Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62(2):241-8.
-
(2005)
Arch Neurol.
, vol.62
, Issue.2
, pp. 241-248
-
-
-
17
-
-
15844386001
-
Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial
-
1:CAS:528:DC%2BD2MXitlOhtL8%3D 15766996
-
Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet. 2005;365(9463):947-54.
-
(2005)
Lancet
, vol.365
, Issue.9463
, pp. 947-954
-
-
Rascol, O.1
Brooks, D.J.2
Melamed, E.3
Oertel, W.4
Poewe, W.5
Stocchi, F.6
-
18
-
-
0034738387
-
Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline
-
1:CAS:528:DC%2BD3cXmtlGktr4%3D 10996018
-
Maruyama W, Yamamoto T, Kitani K, Carrillo MC, Youdim M, Naoi M. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech Ageing Dev. 2000;116(2-3):181-91.
-
(2000)
Mech Ageing Dev
, vol.116
, Issue.2-3
, pp. 181-191
-
-
Maruyama, W.1
Yamamoto, T.2
Kitani, K.3
Carrillo, M.C.4
Youdim, M.5
Naoi, M.6
-
19
-
-
0032999575
-
Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse
-
1:CAS:528:DyaK1MXhtFaru7w%3D 10082192
-
Huang W, Chen Y, Shohami E, Weinstock M. Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse. Eur J Pharmacol. 1999;366(2-3):127-35.
-
(1999)
Eur J Pharmacol
, vol.366
, Issue.2-3
, pp. 127-135
-
-
Huang, W.1
Chen, Y.2
Shohami, E.3
Weinstock, M.4
-
20
-
-
12244296145
-
Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition
-
1:CAS:528:DC%2BD2MXltlCltA%3D%3D 15573406
-
Youdim MB, Bar Am O, Yogev-Falach M, Weinreb O, Maruyama W, Naoi M, et al. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. J Neurosci Res. 2005;79(1-2):172-9.
-
(2005)
J Neurosci Res
, vol.79
, Issue.1-2
, pp. 172-179
-
-
Youdim, M.B.1
Bar Am, O.2
Yogev-Falach, M.3
Weinreb, O.4
Maruyama, W.5
Naoi, M.6
-
21
-
-
2342655732
-
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease
-
Parkinson Study Group
-
Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004;61(4):561-6.
-
(2004)
Arch Neurol.
, vol.61
, Issue.4
, pp. 561-566
-
-
-
22
-
-
67651165337
-
Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease
-
Hauser RA, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ. Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. Mov Disord Off J Mov Disord Soc. 2009;24(4):564-73.
-
(2009)
Mov Disord off J Mov Disord Soc
, vol.24
, Issue.4
, pp. 564-573
-
-
Hauser, R.A.1
Lew, M.F.2
Hurtig, H.I.3
Ondo, W.G.4
Wojcieszek, J.5
Fitzer-Attas, C.J.6
-
23
-
-
61449173973
-
A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics
-
Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord Off J Mov Disord Soc. 2008;23(15):2194-201.
-
(2008)
Mov Disord off J Mov Disord Soc
, vol.23
, Issue.15
, pp. 2194-2201
-
-
Olanow, C.W.1
Hauser, R.A.2
Jankovic, J.3
Langston, W.4
Lang, A.5
Poewe, W.6
-
24
-
-
70349456475
-
A double-blind, delayed-start trial of rasagiline in Parkinson's disease
-
1:CAS:528:DC%2BD1MXht1Wjt7rK 19776408
-
Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. New Engl J Med. 2009;361(13):1268-78.
-
(2009)
New Engl J Med.
, vol.361
, Issue.13
, pp. 1268-1278
-
-
Olanow, C.W.1
Rascol, O.2
Hauser, R.3
Feigin, P.D.4
Jankovic, J.5
Lang, A.6
-
25
-
-
33750026173
-
Safinamide: From molecular targets to a new anti-Parkinson drug
-
1:CAS:528:DC%2BD28XhtVeqsLfL 17030736
-
Caccia C, Maj R, Calabresi M, Maestroni S, Faravelli L, Curatolo L, et al. Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006;67(7 Suppl 2):S18-23.
-
(2006)
Neurology.
, vol.67
, Issue.7
, pp. S18-S23
-
-
Caccia, C.1
Maj, R.2
Calabresi, M.3
Maestroni, S.4
Faravelli, L.5
Curatolo, L.6
-
26
-
-
84855957418
-
A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients
-
1:CAS:528:DC%2BC38XhsVWmsL7J
-
Stocchi F, Borgohain R, Onofrj M, Schapira AH, Bhatt M, Lucini V, et al. A randomized, double-blind, placebo-controlled trial of safinamide as add-on therapy in early Parkinson's disease patients. Mov Disord Off J Mov Disord Soc. 2012;27(1):106-12.
-
(2012)
Mov Disord off J Mov Disord Soc
, vol.27
, Issue.1
, pp. 106-112
-
-
Stocchi, F.1
Borgohain, R.2
Onofrj, M.3
Schapira, A.H.4
Bhatt, M.5
Lucini, V.6
-
27
-
-
84872367500
-
Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease
-
1:STN:280:DC%2BC38bmtV2qsw%3D%3D
-
Schapira AH, Stocchi F, Borgohain R, Onofrj M, Bhatt M, Lorenzana P, et al. Long-term efficacy and safety of safinamide as add-on therapy in early Parkinson's disease. Eur J Neurol Off J Eur Fed Neurol Soc. 2013;20(2):271-80.
-
(2013)
Eur J Neurol off J Eur Fed Neurol Soc
, vol.20
, Issue.2
, pp. 271-280
-
-
Schapira, A.H.1
Stocchi, F.2
Borgohain, R.3
Onofrj, M.4
Bhatt, M.5
Lorenzana, P.6
-
28
-
-
84894251130
-
Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations
-
1:CAS:528:DC%2BC2cXjt1ymsL4%3D
-
Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, et al. Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord Off J Mov Disord Soc. 2014;29(2):229-37.
-
(2014)
Mov Disord off J Mov Disord Soc
, vol.29
, Issue.2
, pp. 229-237
-
-
Borgohain, R.1
Szasz, J.2
Stanzione, P.3
Meshram, C.4
Bhatt, M.5
Chirilineau, D.6
-
29
-
-
0024848034
-
Abnormalities of the electron transport chain in idiopathic Parkinson's disease
-
2557792
-
Parker WD Jr, Boyson SJ, Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol. 1989;26(6):719-23.
-
(1989)
Ann Neurol.
, vol.26
, Issue.6
, pp. 719-723
-
-
Parker, W.D.1
Boyson, S.J.2
Parks, J.K.3
-
30
-
-
0033001416
-
A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease
-
1:CAS:528:DyaK1MXkt12mtr8%3D 10416040
-
Shults CW, Haas RH, Beal MF. A possible role of coenzyme Q10 in the etiology and treatment of Parkinson's disease. BioFactors. 1999;9(2-4):267-72.
-
(1999)
BioFactors
, vol.9
, Issue.2-4
, pp. 267-272
-
-
Shults, C.W.1
Haas, R.H.2
Beal, M.F.3
-
31
-
-
0036771852
-
Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline
-
12374491
-
Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002;59(10):1541-50.
-
(2002)
Arch Neurol
, vol.59
, Issue.10
, pp. 1541-1550
-
-
Shults, C.W.1
Oakes, D.2
Kieburtz, K.3
Beal, M.F.4
Haas, R.5
Plumb, S.6
-
32
-
-
84900479240
-
A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: No evidence of benefit
-
24664227
-
Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, et al. A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit. JAMA Neurol. 2014;71(5):543-52.
-
(2014)
JAMA Neurol
, vol.71
, Issue.5
, pp. 543-552
-
-
Beal, M.F.1
Oakes, D.2
Shoulson, I.3
Henchcliffe, C.4
Galpern, W.R.5
Haas, R.6
-
33
-
-
0035002174
-
Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders
-
1:CAS:528:DC%2BD3MXjvFKhu7k%3D 11357946
-
Tarnopolsky MA, Beal MF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann Neurol. 2001;49(5):561-74.
-
(2001)
Ann Neurol.
, vol.49
, Issue.5
, pp. 561-574
-
-
Tarnopolsky, M.A.1
Beal, M.F.2
-
34
-
-
0032914740
-
Creatine and cyclocreatine attenuate MPTP neurotoxicity
-
1:CAS:528:DyaK1MXis1Klurk%3D 10222117
-
Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, et al. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol. 1999;157(1):142-9.
-
(1999)
Exp Neurol
, vol.157
, Issue.1
, pp. 142-149
-
-
Matthews, R.T.1
Ferrante, R.J.2
Klivenyi, P.3
Yang, L.4
Klein, A.M.5
Mueller, G.6
-
35
-
-
33645894705
-
A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease
-
NINDS NET-PD Investigators
-
NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006;66(5):664-71.
-
(2006)
Neurology.
, vol.66
, Issue.5
, pp. 664-671
-
-
-
36
-
-
84922485882
-
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: A randomized clinical trial
-
25668262
-
Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, et al. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015;313(6):584-93.
-
(2015)
JAMA
, vol.313
, Issue.6
, pp. 584-593
-
-
Kieburtz, K.1
Tilley, B.C.2
Elm, J.J.3
Babcock, D.4
Hauser, R.5
Ross, G.W.6
-
37
-
-
34347359673
-
'Rejuvenation' protects neurons in mouse models of Parkinson's disease
-
1:CAS:528:DC%2BD2sXmvFKmurY%3D 17558391
-
Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, et al. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature. 2007;447(7148):1081-6.
-
(2007)
Nature
, vol.447
, Issue.7148
, pp. 1081-1086
-
-
Chan, C.S.1
Guzman, J.N.2
Ilijic, E.3
Mercer, J.N.4
Rick, C.5
Tkatch, T.6
-
38
-
-
0030601952
-
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level
-
1:CAS:528:DyaK28XmvFaktr8%3D 9001722
-
Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res. 1996;741(1-2):185-96.
-
(1996)
Brain Res
, vol.741
, Issue.1-2
, pp. 185-196
-
-
Kupsch, A.1
Sautter, J.2
Schwarz, J.3
Riederer, P.4
Gerlach, M.5
Oertel, W.H.6
-
39
-
-
79958204001
-
The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease
-
3235730 1:CAS:528:DC%2BC3MXnsFWhu70%3D 21515375
-
Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis. 2011;43(2):364-71.
-
(2011)
Neurobiol Dis
, vol.43
, Issue.2
, pp. 364-371
-
-
Ilijic, E.1
Guzman, J.N.2
Surmeier, D.J.3
-
40
-
-
77951735527
-
L-type calcium channel blockers and Parkinson disease in Denmark
-
2917467 1:CAS:528:DC%2BC3cXmvF2lsrw%3D 20437557
-
Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. L-type calcium channel blockers and Parkinson disease in Denmark. Ann Neurol. 2010;67(5):600-6.
-
(2010)
Ann Neurol.
, vol.67
, Issue.5
, pp. 600-606
-
-
Ritz, B.1
Rhodes, S.L.2
Qian, L.3
Schernhammer, E.4
Olsen, J.H.5
Friis, S.6
-
41
-
-
84859509751
-
Use of calcium channel blockers and Parkinson's disease
-
22387374
-
Pasternak B, Svanstrom H, Nielsen NM, Fugger L, Melbye M, Hviid A. Use of calcium channel blockers and Parkinson's disease. Am J Epidemiol. 2012;175(7):627-35.
-
(2012)
Am J Epidemiol
, vol.175
, Issue.7
, pp. 627-635
-
-
Pasternak, B.1
Svanstrom, H.2
Nielsen, N.M.3
Fugger, L.4
Melbye, M.5
Hviid, A.6
-
42
-
-
78650183301
-
Tolerability of isradipine in early Parkinson's disease: A pilot dose escalation study
-
Simuni T, Borushko E, Avram MJ, Miskevics S, Martel A, Zadikoff C, et al. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov Disord Off J Mov Disord Soc. 2010;25(16):2863-6.
-
(2010)
Mov Disord off J Mov Disord Soc
, vol.25
, Issue.16
, pp. 2863-2866
-
-
Simuni, T.1
Borushko, E.2
Avram, M.J.3
Miskevics, S.4
Martel, A.5
Zadikoff, C.6
-
43
-
-
84887625913
-
Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)
-
1:CAS:528:DC%2BC3sXhsl2hur%2FO
-
Simuni T, Biglan K, Oakes D, et al. Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD). Mov Disord Off J Mov Disord Soc. 2013;28(13):1823-31.
-
(2013)
Mov Disord off J Mov Disord Soc.
, vol.28
, Issue.13
, pp. 1823-1831
-
-
Simuni, T.1
Biglan, K.2
Oakes, D.3
-
45
-
-
34548021226
-
Plasma urate and risk of Parkinson's disease
-
2391073 1:STN:280:DC%2BD2svmvFCmsQ%3D%3D 17584757
-
Weisskopf MG, O'Reilly E, Chen H, Schwarzschild MA, Ascherio A. Plasma urate and risk of Parkinson's disease. Am J Epidemiol. 2007;166(5):561-7.
-
(2007)
Am J Epidemiol
, vol.166
, Issue.5
, pp. 561-567
-
-
Weisskopf, M.G.1
O'Reilly, E.2
Chen, H.3
Schwarzschild, M.A.4
Ascherio, A.5
-
46
-
-
45149122797
-
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease
-
2574855 18413464
-
Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, et al. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716-23.
-
(2008)
Arch Neurol
, vol.65
, Issue.6
, pp. 716-723
-
-
Schwarzschild, M.A.1
Schwid, S.R.2
Marek, K.3
Watts, A.4
Lang, A.E.5
Oakes, D.6
-
47
-
-
73549111772
-
Urate as a predictor of the rate of clinical decline in Parkinson disease
-
2795011 19822770
-
Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, et al. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66(12):1460-8.
-
(2009)
Arch Neurol
, vol.66
, Issue.12
, pp. 1460-1468
-
-
Ascherio, A.1
LeWitt, P.A.2
Xu, K.3
Eberly, S.4
Watts, A.5
Matson, W.R.6
-
48
-
-
84893841038
-
Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: A randomized clinical trial
-
24366103
-
Schwarzschild MA, Ascherio A, Beal MF, Cudkowicz ME, Curhan GC, Hare JM, et al. Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial. JAMA Neurol. 2014;71(2):141-50.
-
(2014)
JAMA Neurol
, vol.71
, Issue.2
, pp. 141-150
-
-
Schwarzschild, M.A.1
Ascherio, A.2
Beal, M.F.3
Cudkowicz, M.E.4
Curhan, G.C.5
Hare, J.M.6
-
49
-
-
0347087323
-
Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation
-
1:CAS:528:DC%2BD2cXntlWjug%3D%3D 14690537
-
Dehmer T, Heneka MT, Sastre M, Dichgans J, Schulz JB. Protection by pioglitazone in the MPTP model of Parkinson's disease correlates with I kappa B alpha induction and block of NF kappa B and iNOS activation. J Neurochem. 2004;88(2):494-501.
-
(2004)
J Neurochem
, vol.88
, Issue.2
, pp. 494-501
-
-
Dehmer, T.1
Heneka, M.T.2
Sastre, M.3
Dichgans, J.4
Schulz, J.B.5
-
50
-
-
79961103714
-
The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys
-
1:CAS:528:DC%2BC3MXhtFegsbfP
-
Swanson CR, Joers V, Bondarenko V, Brunner K, Simmons HA, Ziegler TE, et al. The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflamm. 2011;8:91.
-
(2011)
J Neuroinflamm
, vol.8
, pp. 91
-
-
Swanson, C.R.1
Joers, V.2
Bondarenko, V.3
Brunner, K.4
Simmons, H.A.5
Ziegler, T.E.6
-
51
-
-
84937520622
-
A phase 2, multicentre, double-blind, randomised trial
-
Lancet Neurol. (Epub 2015/06/28).
-
Simuni T, Kieburtz K, Tilley B, et al. Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015 (Epub 2015/06/28).
-
(2015)
Pioglitazone in Early Parkinson's Disease
-
-
Simuni, T.1
Kieburtz, K.2
Tilley, B.3
-
52
-
-
59049087723
-
GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism
-
2633544 1:CAS:528:DC%2BD1MXhsFyiurc%3D 19164583
-
Li Y, Perry T, Kindy MS, Harvey BK, Tweedie D, Holloway HW, et al. GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism. Proc Natl Acad Sci USA. 2009;106(4):1285-90.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, Issue.4
, pp. 1285-1290
-
-
Li, Y.1
Perry, T.2
Kindy, M.S.3
Harvey, B.K.4
Tweedie, D.5
Holloway, H.W.6
-
53
-
-
45549108268
-
Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease
-
Harkavyi A, Abuirmeileh A, Lever R, Kingsbury AE, Biggs CS, Whitton PS. Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflamm. 2008;5:19.
-
(2008)
J Neuroinflamm
, vol.5
, pp. 19
-
-
Harkavyi, A.1
Abuirmeileh, A.2
Lever, R.3
Kingsbury, A.E.4
Biggs, C.S.5
Whitton, P.S.6
-
54
-
-
84904126994
-
Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease
-
1:CAS:528:DC%2BC2cXhvFeit7%2FP
-
Aviles-Olmos I, Dickson J, Kefalopoulou Z, Djamshidian A, Kahan J, Ell P, et al. Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease. J Parkinson's Dis. 2014;4(3):337-44.
-
(2014)
J Parkinson's Dis
, vol.4
, Issue.3
, pp. 337-344
-
-
Aviles-Olmos, I.1
Dickson, J.2
Kefalopoulou, Z.3
Djamshidian, A.4
Kahan, J.5
Ell, P.6
-
55
-
-
34447255185
-
Pooled analysis of tobacco use and risk of Parkinson disease
-
17620489
-
Ritz B, Ascherio A, Checkoway H, Marder KS, Nelson LM, Rocca WA, et al. Pooled analysis of tobacco use and risk of Parkinson disease. Arch Neurol. 2007;64(7):990-7.
-
(2007)
Arch Neurol
, vol.64
, Issue.7
, pp. 990-997
-
-
Ritz, B.1
Ascherio, A.2
Checkoway, H.3
Marder, K.S.4
Nelson, L.M.5
Rocca, W.A.6
-
56
-
-
4444230502
-
Fernandez-Crehuet Navajas R. Smoking and Parkinson's disease: Systematic review of prospective studies
-
Allam MF, Campbell MJ, Hofman A, Del Castillo AS. Fernandez-Crehuet Navajas R. Smoking and Parkinson's disease: systematic review of prospective studies. Mov Disord Off J Mov Disord Soc. 2004;19(6):614-21.
-
(2004)
Mov Disord off J Mov Disord Soc
, vol.19
, Issue.6
, pp. 614-621
-
-
Allam, M.F.1
Campbell, M.J.2
Hofman, A.3
Del, C.A.4
-
57
-
-
33947546011
-
Temporal relationship between cigarette smoking and risk of Parkinson disease
-
2225169 1:CAS:528:DC%2BD2sXitFyqsbY%3D 17339584
-
Thacker EL, O'Reilly EJ, Weisskopf MG, Chen H, Schwarzschild MA, McCullough ML, et al. Temporal relationship between cigarette smoking and risk of Parkinson disease. Neurology. 2007;68(10):764-8.
-
(2007)
Neurology.
, vol.68
, Issue.10
, pp. 764-768
-
-
Thacker, E.L.1
O'Reilly, E.J.2
Weisskopf, M.G.3
Chen, H.4
Schwarzschild, M.A.5
McCullough, M.L.6
-
58
-
-
0026327733
-
Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the mesodiencephalic junction in rats: A microdialysis study
-
1:STN:280:DyaK383ntVWhtw%3D%3D 1815152
-
Janson AM, Meana JJ, Goiny M, Herrera-Marschitz M. Chronic nicotine treatment counteracts the decrease in extracellular neostriatal dopamine induced by a unilateral transection at the mesodiencephalic junction in rats: a microdialysis study. Neurosci Lett. 1991;134(1):88-92.
-
(1991)
Neurosci Lett
, vol.134
, Issue.1
, pp. 88-92
-
-
Janson, A.M.1
Meana, J.J.2
Goiny, M.3
Herrera-Marschitz, M.4
-
59
-
-
33748159130
-
Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates
-
1:CAS:528:DC%2BD28XhtVCksb7I 16882311
-
Quik M, Parameswaran N, McCallum SE, Bordia T, Bao S, McCormack A, et al. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J Neurochem. 2006;98(6):1866-75.
-
(2006)
J Neurochem
, vol.98
, Issue.6
, pp. 1866-1875
-
-
Quik, M.1
Parameswaran, N.2
McCallum, S.E.3
Bordia, T.4
Bao, S.5
McCormack, A.6
-
60
-
-
0037185083
-
Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture
-
1:CAS:528:DC%2BD38XktVKlsQ%3D%3D 11801364
-
Jeyarasasingam G, Tompkins L, Quik M. Stimulation of non-alpha7 nicotinic receptors partially protects dopaminergic neurons from 1-methyl-4-phenylpyridinium-induced toxicity in culture. Neuroscience. 2002;109(2):275-85.
-
(2002)
Neuroscience
, vol.109
, Issue.2
, pp. 275-285
-
-
Jeyarasasingam, G.1
Tompkins, L.2
Quik, M.3
-
61
-
-
0037382337
-
Nicotine protects rat brain mitochondria against experimental injuries
-
1:CAS:528:DC%2BD3sXisFWnsL4%3D 12668050
-
Cormier A, Morin C, Zini R, Tillement JP, Lagrue G. Nicotine protects rat brain mitochondria against experimental injuries. Neuropharmacology. 2003;44(5):642-52.
-
(2003)
Neuropharmacology
, vol.44
, Issue.5
, pp. 642-652
-
-
Cormier, A.1
Morin, C.2
Zini, R.3
Tillement, J.P.4
Lagrue, G.5
-
62
-
-
69149089854
-
Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein
-
2722313 1:CAS:528:DC%2BD1MXhtVKru7%2FM 19651612
-
Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA. 2009;106(31):13010-5.
-
(2009)
Proc Natl Acad Sci USA
, vol.106
, Issue.31
, pp. 13010-13015
-
-
Desplats, P.1
Lee, H.J.2
Bae, E.J.3
Patrick, C.4
Rockenstein, E.5
Crews, L.6
-
63
-
-
84869109864
-
Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice
-
3552321 1:CAS:528:DC%2BC38Xhs1GntL7L 23161999
-
Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, et al. Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science. 2012;338(6109):949-53.
-
(2012)
Science
, vol.338
, Issue.6109
, pp. 949-953
-
-
Luk, K.C.1
Kehm, V.2
Carroll, J.3
Zhang, B.4
O'Brien, P.5
Trojanowski, J.Q.6
-
64
-
-
43249114934
-
Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease
-
1:CAS:528:DC%2BD1cXlsFCmsrg%3D 18391962
-
Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med. 2008;14(5):504-6.
-
(2008)
Nat Med
, vol.14
, Issue.5
, pp. 504-506
-
-
Kordower, J.H.1
Chu, Y.2
Hauser, R.A.3
Freeman, T.B.4
Olanow, C.W.5
|